Clinical Trial Update: Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) [Phase 2, Phase 3]

View source ↗

Summary

Clinical update on a multicenter Phase 2/Phase 3 trial evaluating cysteamine (RP103) for Huntington's disease. The current status of the study is not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Cysteamine (RP103) (cysteamine)

Snippet

Sponsor: University Hospital, Angers | Conditions: Huntington's Disease | Phase 2, Phase 3 | Status: UNKNOWN